Multiple Myeloma Clinical Trials & Emerging Therapies
Clinical trials are essential to the development of new multiple myeloma treatments.
This page describes the importance of clinical trials and emerging therapies for multiple myeloma, highlights the Horizon Clinical Trials Program and its first two studies (Horizon One and Horizon Two), outlines the clinical‑trial phases, and lists several investigational drugs and therapies in development.
Participation in clinical trials gives patients access to new therapies that may be more effective or have fewer side effects than existing options and contributes to scientific knowledge about disease biology and treatment response.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- A single‑cell atlas of multiple myeloma defines malignant archetypes and proliferative states
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy
- Genomic profiling enables personalized strategies to overcome drug resistance in multiple myeloma